Is Taro Pharmaceutical Industries Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NYSE: TARO) stock is to Hold TARO stock.
Out of 1 analyst, 0 (0%) are recommending TARO as a Strong Buy, 0 (0%) are recommending TARO as a Buy, 1 (100%) are recommending TARO as a Hold, 0 (0%) are recommending TARO as a Sell, and 0 (0%) are recommending TARO as a Strong Sell.
What is TARO's revenue growth forecast for 2024-2024?
(NYSE: TARO) Taro Pharmaceutical Industries's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Taro Pharmaceutical Industries's revenue in 2024 is $610,828,000.
In 2024, TARO is forecast to generate $23,232,667,481 in revenue, with the lowest revenue forecast at $23,232,667,481 and the highest revenue forecast at $23,232,667,481.
What is TARO's forecast return on assets (ROA) for 2024-2024?
(NYSE: TARO) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 9.86%.
What is TARO's Price Target?
According to 1 Wall Street analyst that have issued a 1 year TARO price target, the average TARO price target is $43.00, with the highest TARO stock price forecast at $43.00 and the lowest TARO stock price forecast at $43.00.
The Wall Street analyst predicted that Taro Pharmaceutical Industries's share price could reach $43.00 by Jan 18, 2025. The average Taro Pharmaceutical Industries stock price prediction forecasts a potential upside of 1.56% from the current TARO share price of $42.34.
What is TARO's forecast return on equity (ROE) for 2024-2024?
(NYSE: TARO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.